Dispatcher-assisted bystander CPR: a KISS for a kiss
暂无分享,去创建一个
[1] H. Parving,et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial , 2010, The Lancet.
[2] M. Tokumoto,et al. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality , 2010, The Journal of Steroid Biochemistry and Molecular Biology.
[3] N. Fujii,et al. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. , 2009, Bone.
[4] S. Fishbane,et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] G. Cockrell,et al. Microalbuminuria in Type 1 Diabetes Is Associated With Enhanced Excretion of the Endocytic Multiligand Receptors Megalin and Cubilin , 2009, Diabetes Care.
[6] Zhongyi Zhang,et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. , 2008, Kidney international.
[7] G. Ning,et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. , 2008, Kidney international.
[8] D. Batlle,et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. , 2005, Kidney international.
[9] M. Wolf,et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. , 2003, The New England journal of medicine.
[10] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .